HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 9, September 2016 – Infectious Diseases       » Curcumin Derivatives May Prevent Alzheimer's Disease by Promoting Amyloid- Clearance       » Varian Chosen to Equip First Government Owned Proton Centre in China       » Medtronic and SingHealth Collaborate on a Centre of Excellence to Fight Diabetes       » NCCS Awards Contract for Proton Beam Therapy System to Hitachi Asia      
EYE ON CHINA
to-BBB and Sihuan enter into collaboration agreement

To-BBB, a brain drug development company, is entering into a collaboration agreement with Sun Moral International (HK) Limited, a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings Group Limited. The agreement aims at the collaborative research and development of innovative drugs for Central Nervous System (CNS) diseases.

to-BBB and Sihuan will conduct feasibility studies by applying to-BBB's G-Technology®, a patented brain drug delivery technology for sustained release and enhanced brain delivery, to certain drug compounds owned by Sihuan. Based on the successful completion of the feasibility studies, both parties desire to enter into a commercial license agreement for collaborative development of one or more drug compounds using to-BBB's G-Technology.

Sihuan shall pursue the approval of the developed products in China. "Sihuan entered into the collaboration agreement with the aim to tap the high unmet medical need of drug products with sustained delivery to the CNS," says Dr. Che FengSheng, CEO and Chairman of Sihuan. "The collaboration will combine the research efforts of to-BBB's brain targeting technology and Sihuan's R&D resources in oncology and CNS. The R&D program will be overseen by a joint steering committee with representatives from to-BBB and Sihuan. The two parties will share the achievements of the R&D project."

"We are pleased by Sihuan's recognition that the G-Technology offers the safest possibility to enhance the delivery of drugs across the blood-brain barrier, aiming at therapeutic approaches for treating devastating CNS diseases," says Dr. Pieter Gaillard, CSO of to-BBB. "This unique approach has obtained multiple pre-clinical and clinical validations, including the development of to-BBB's lead product 2B3-101 for brain cancer that is currently in a Phase IIa trial."

Click here for the complete issue.

NEWS CRUNCH  
news Enterprise meets technology: More than 300 enabling innovations showcased at TechInnovation
news CPhI's Pre-Connect Congress outlines current trends in pharma
news World Population Day 2016
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Big Data in Healthcare
December:
Orthopaedics
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy